Your browser has either disabled or does not support javascript. Javascript is required for full website experience.
Aeglea BioTherapeutics Inc
AGLE
$
7.68
-3.9%
Mon October 26th, 2020
12:30
Press Releases
Aeglea BioTherapeutics Announces U.S. and EU Orphan Drug Designations for ACN00177 for the Treatment of Homocystinuria
PR Newswire
Mon October 5th, 2020
20:30
Press Releases
Aeglea BioTherapeutics Announces Presentations on Arginase 1 Deficiency and Homocystinuria Programs at Two Upcoming Virtual Medical Meetings
PR Newswire
Tue August 25th, 2020
12:40
Analysis
Aeglea (AGLE) Looks Good: Stock Adds 5.8% in Session
Zacks
Mon June 29th, 2020
16:00
Analysis
Here's Why Momentum Investors Will Love Aeglea Biotherapeutics (AGLE)
Zacks
Tue June 23rd, 2020
12:47
Analysis
Aeglea BioTherapeutics (AGLE) Catches Eye: Stock Jumps 5.1%
Zacks
Wed June 10th, 2020
15:30
Analysis
Has Aeglea BioTherapeutics (AGLE) Outpaced Other Medical Stocks This Year?
Zacks
Mon June 8th, 2020
13:03
Analysis
Why Aeglea BioTherapeutics (AGLE) Stock Might be a Great Pick
Zacks
+ 2 more
Thu June 4th, 2020
15:17
Press Releases
Analysis
Zacks.com featured highlights include: Aeglea BioTherapeutics and Passage Bio
Zacks
Mon June 1st, 2020
20:05
Press Releases
Aeglea BioTherapeutics to Present at BIO Digital 2020
Benzinga
Fri May 29th, 2020
15:49
Analysis
Aeglea BioTherapeutics' Shares March Higher, Can It Continue?
Zacks
Thu May 21st, 2020
15:30
Analysis
Is Aeglea BioTherapeutics (AGLE) Outperforming Other Medical Stocks This Year?
Zacks
Wed May 20th, 2020
12:56
Press Releases
Analysis
Zacks.com featured highlights include: Aeglea BioTherapeutics, VeriSign, Sequans Communications and New Jersey Resources
Zacks
